Satellite Symposia

Satellite symposia are non-commercial, grant- funded learning activities that are planned and conducted by the corporate community in conjunction with AMCP 2024. Satellite symposia offer continuing pharmacy education (CPE) credit, and some offer continuing medical education (CME) credit and continuing nursing education (CNE) credit. 

Registration, content, and continuing education are the sole responsibility of the provider. There is no fee for pre-registering for these educational activities, as registration is for planning purposes only. 

The satellite symposia schedule will be posted no later than mid-February.

For more information, please contact us.

Satellite Symposia Guidelines
The UPS Store - Shipping Instructions 


Monday, Apr. 15, 2024|6-8pm

Managed Care Review Board™ Presents: Managed Care Considerations on the Emerging Role of Bispecific Antibodies in Non-Hodgkin’s Lymphoma

Location: 215-216

  • Jointly Provided by: Impact Education, LLC and Partners for Advancing Clinical Education
  • Supported by: Regeneron Pharmaceuticals, Inc.
  • Continuing education: The primary target audience for this activity consists of managed care pharmacy directors, clinical pharmacists, quality directors, medical directors, members of the AMCP, and other managed health care professionals attending AMCP 2024.
  • 1.5 CPE/CME/CNE credit hours available

    Program Description:


The expanding array of therapeutic strategies for Non-Hodgkin's Lymphoma (NHL) poses an ongoing challenge in optimal treatment selection and sequencing. Despite notable advancements in disease management and patient survival, many individuals still face disease relapse or encounter treatment-limiting toxicities. Bispecific antibodies (BsAbs) employ elements from diverse antibodies to offer targeted therapeutic approaches, particularly for hematologic malignancies like lymphomas. As clinical evidence supporting the use of BsAbs in hematologic malignancies continues to emerge, managed care pharmacists will need to identify formulary and utilization management strategies that effectively incorporate BsAbs into the current treatment armamentarium. Leverage the expertise of this interactive multistakeholder panel discussion to understand the role of emerging innovative treatments, optimize outcomes, and enhance the care of patients with relapsed/refractory NHL.

Learning Objectives:

  • Describe current evidence-based recommendations for the treatment of Non-Hodgkin's Lymphoma (NHL)
  • Explore the structural properties, clinical benefits, and safety of bispecific antibodies (BsAbs) for patients with relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma
  • Analyze clinical trial data to clarify the place in therapy for BsAbs in the treatment of relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma
  • Describe the burdens of relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma on patients
  • Assess how reimbursement policies can be developed to align with broader goals to reduce NHL morbidity and mortality

    Program Manager:

    Allison Hartless
    Impact Education, LLC
    allison.hartless@impactedu.net

    Registration Link: Coming Soon
     
Application of Recent Data in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: Managed Care Insights and Strategies

Location: 224

  • Provider: Pharmacy Times Continuing Education
  • Supported by: Genentech, a member of the Roche Group.
  • Continuing education: Managed care pharmacists, physicians, and nurses
  • Contact hours: 1.5

    Program Description:

    Neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) are retinal conditions that are the leading causes of vision loss worldwide. Optimal treatment outcomes depend on patient adherence, timely treatment initiation, and continuation of therapy, which underscores the importance of tailored management strategies. Recent therapy advancements include intravitreal agents with improved durability allowing for increased time between injections. Managed care professionals are uniquely positioned to ensure the safe and effective use of these medications while facilitating the exchange of information between pharmacists and physicians. With an enhanced understanding of the current landscape and treatment strategies for nAMD and DME, managed care professionals can effectively analyze current drug formularies and actively implement new treatment options. This activity will review current and emerging treatment options, therapeutic challenges, and the role of managed care professionals in optimizing management for nAMD and DME. Overall, managed care professionals will be better informed about clinical decisions, which can lead to improved patient outcomes and quality of life.

    Learning Objectives:
  • Explore the latest research on innovative therapies for managing neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).
  • Analyze new treatment approaches that can decrease the burden of care for patients with nAMD and DME.
  • Identify the best practices for managed care professionals to integrate recent updates to their practice and enhance outcomes for patients with nAMD and DME.

    Program Manager:
    Kylie Ferrentino
    Pharmacy Times Continuing Education
    kferrentino@pharmacytimes.com

    Registration Link: Coming Soon

Tuesday, Apr. 16, 2024|6:30am-8:30am 

Mock P&T: Examining the Latest Evidence in the Treatment of Perinatal/Peripartum Depression

Location: 206

  • Provider: Provided by PRME Education
  • Supported by: Sage Therapeutics, Inc.
  • Continuing education: Medical and pharmacy directors, pharmacists, and medication therapy management (MTM) nursing directors working in managed care organizations.
  • Contact hours: 1.5

    Program Description:

    Equipped with cutting-edge treatment advancements and the most recent research findings in perinatal/peripartum depression (PPD), professionals in managed care pharmacy are confronted with challenging choices regarding patient selection. On April 16th, join leading experts live in person in New Orleans or via livestream for this unique session at the 2024 AMCP Annual Meeting, designed as a mock Pharmacy and Therapeutics (P&T) Committee meeting to involve managed care decision-makers in an interactive learning experience that can be applied in the real-world setting.

    A panel of esteemed experts will delve into discussions and deliberations on the existing PPD guidelines, the available data concerning novel therapies, and the imperative to strike a balance between clinical effectiveness and financial constraints linked to patients with PPD. Participants will have opportunities to actively engage with the committee and contribute to consensus-building processes.

    Learning Objectives:
  • Describe the physical, emotional and behavioral consequences of undiagnosed and untreated perinatal/peripartum depression (PPD) on maternal and neonatal outcomes
  • Discuss how neuroactive steroids may influence the expression of PPD symptoms
  • Evaluate current clinical data, evidence-based guidelines, and prior authorization requirements for appropriate integration of new and emerging neuroactive steroid therapies for PPD
  • Align managed care decision-making frameworks with current evidence regarding the safety, efficacy, and cost-effectiveness of PPD therapies

    Agenda:
I.  Program Introduction and Overview of Mock P&T Committee Meeting Format
II. Real-World Patient Perspectives: Impact of PPD
III.Updates on the Latest Evidence on the Treatment and Management of PPD
         a. Addressing “Top of Mind” Questions for Managed Care Decision-Makers
         b. Association of Pathophysiology of PPD With Neuroactive Steroid Therapies
         c. Clinical Trial Results and Application to Unmet Patient Needs
IV. Overview of Hypothetical Health Plan for Mock P&T Committee Meeting
V. Managed Care Decision-Making About Neuroactive Steroids for PPD
VI. The P&T Committee Convenes
       a. Expert Opinions by the Mock P&T Committee Panel
       b. Audience Volunteers and Committee Members
VII. Sharing Results and Informing Next Steps
      a. Mock P&T Committee Silently Votes
      b. Audience Votes Via Polling
      c. Results Revealed
VIII. Closing Remarks
      a. Lessons Learned and Applications to Managed Care Decision-Making

Program Manager

Stephanie Yang
PRIME Education
s.yang@primeinc.org

Register Now
 

Novel Therapies and Emerging Strategies for HR+/HER2– Metastatic Breast Cancer and the Impact on Patient Outcomes | Short title: Emerging Strategies for HR+/HER2– Metastatic Breast Cancer and the Impact on Patient Outcomes

Location: 224

  • Provider: Pharmacy Times Continuing Education
  • Supported by: Novartis
  • Continuing education: Pharmacists, managed care
  • Contact hours: 1.5


Program Description:

A hallmark of treatment for patients with HR+/HER2– metastatic breast cancer (MBC) continues to be cyclin-dependent kinase 4 and 6 (CKD4/6) inhibitors. Several novel targeted therapies are emerging for these patients, including oral selective estrogen receptor downregulators (SERDs) and AKT inhibitors. However, these developments also bring several challenges. Questions remain regarding the optimal treatment strategy for patients who progress on frontline CDK4/6 regimens. Additionally, suboptimal adherence to therapy and treatment-related toxicities can contribute to premature discontinuation of therapy and are substantial barriers to achieving optimal patient outcomes. Managed care professionals and pharmacists must be familiar with clinical evidence for these emerging therapies to facilitate their inclusion within treatment pathways. This activity will explore the role of managed care professionals and pharmacists in integrating emerging oral SERDs and AKT inhibitors into treatment strategies with or without CDK4/6 inhibitors for patients with HR+/HER2– MBC. The impact of these targeted therapies on on real-world formulary decisions, resource allocation strategies, and patient-reported outcomes will also be discussed.

Learning Objectives:

  • Interpret the guideline-recommended approach to care and the treatment goals for patients with HR+/HER2– advanced and metastatic breast cancer (MBC).
  • Analyze recent clinical updates on novel and emerging pharmacotherapeutic approaches for HR+/HER2– MBC.
  • Explain the impact of recent evidence to the HR+/HER2– MBC treatment paradigm and challenges to implementation of evolving therapies, such as the impact of adjuvant treatment.
  • Apply operational and managed care considerations to integrate recent clinical updates into formulary decisions, pathways, and resource allocation in the management of HR+/HER2– MBC.

    Program Manager:
    Kylie Ferrentino
    Pharmacy Times Continuing Education
    kferrentino@pharmacytimes.com

    Registration Link: Coming soon

Tuesday, Apr. 16, 2024|11:30am-1:30pm

Strategic Excellence: Mastering the Expanding ATTR-CM Therapeutic Landscape in Pharmacy Practice

Location: 206

  • Provider: Medtelligence, Inc.
  • Supported by: This activity is supported by an independent educational grant from BridgeBio.
  • Continuing education: This activity is designed to meet the educational needs of managed care pharmacists, cardiologists, nurse practitioners, and physician associates.
  • Contact hours: 1.5

    Program Description:

    The program emphasizes the latest clinical insights in this evolving therapeutic landscape, addressing changes in diagnostic approaches over the last decade, and providing a nuanced perspective on ATTR-CM progression for more effective patient care. This initiative offers insights into cutting-edge treatment strategies, facilitating timely interventions that impact patient outcomes positively, as well as ensures pharmacists are equipped with actionable treatment strategies and best practices, fostering seamless integration into real-world scenarios. Participation not only expands pharmacists' expertise but also contributes to elevating the standard of care for ATTR-CM patients. Join us in this educational endeavor to empower pharmacists with the latest insights and strategies for improved decision-making in ATTR-CM management. In an open discussion, chairperson Hongya Chen, PharmD, and faculty members will provide an updated review of the disease state (including a better understanding of the mechanism of the disease), and discuss the pathogenic and protective genetic variants along with evidence from clinical trials.

    Learning Objectives:
     
  • Describe the pathophysiology and genetic variation of transthyretin amyloid cardiomyopathy (ATTR-CM)
  • Discuss the clinical manifestations and diagnosis of ATTR-CM
  • Compare the treatment options available for patients with ATTR-CM

    Program Manager:
    Andrea Mathis
    Global Learning Collaborative
    amathis@glc.healthcare

    Register Now
ManagedCareEye.com Presents: Managed Care Review Board™ - Assessing Recent Advances for Enhanced Management of Retinal Diseases
 
Location: 215-216
 
  • Jointly Provided By: Impact Education, LLC and Medical Education Resources
  • Supported by: Regeneron Pharmaceuticals, Inc.
  • Continuing education: The primary target audience for this activity consists of managed care pharmacy directors, clinical pharmacists, quality directors, medical directors, members of the AMCP, and other managed health care professionals attending AMCP 2024.
  • 1.5 CPE/CME/CNE credit hours available

    Program Description:

    Managed care plays a pivotal role in ensuring optimal patient outcomes and cost-effective medication management strategies in retinal disease. Regarding assessing recent treatment advances for retinal diseases, managed care professionals need to stay abreast of emerging treatment modalities and therapeutic breakthroughs. Understanding the mechanisms of action, efficacy profiles, safety considerations, and cost-effectiveness of novel medications and interventions for retinal diseases is crucial to supporting patient adherence to treatment and preventing blindness. Pharmacists should be knowledgeable about the evolving landscape of pharmacotherapy, including anti-vascular endothelial growth factor (anti-VEGF) agents, sustained-release drug delivery systems, and emerging therapies. Leverage the expertise of this interactive multistakeholder panel discussion to optimize treatment outcomes, enhance patient care, and manage health care costs of retinal diseases.


Learning Objectives:
 

  • Evaluate treatment strategies and resources based on evidence for achieving the best patient outcomes in cases of retinal diseases.
  • Describe pharmacological treatments for retinal diseases, considering their effectiveness, safety, and recommended dosing intervals.
  • Assess medical and pharmacy benefit design approaches to streamline patient care to evidence-based treatments for retinal diseases.
  • Outline efforts between payers and providers to enhance the treatment of retinal diseases through education and coordination.

    Program Manager:

    Allison Hartless
    Impact Education, LLC
    allison.hartless@impactedu.net

    Registration Link: Coming Soon
    ​​​​​
    Emerging Concepts and Approaches in the Treatment of Food Allergy: What Managed Care Professionals Need to Know | Short title: Emerging Concepts and Approaches in the Treatment of Food Allergy

    Location: 224

    • Provider: Pharmacy Times Continuing Education
    • Supported by: Genentech, a member if the Roche Group
    • Continuing education: Pharmacists, managed care
    • Contact hours: 1.5​

    Program Description:

    In the US, food allergies can affect both adults and children, with about one-third of children retaining their allergies into adulthood. Current approaches for the management of severe food-related reactions have their limitations. Newer research and guidelines to improve patients’ desensitization and tolerance to food allergens includes a mix of dietary interventions, biological therapies, and allergen immunotherapy. Managed care professionals must be aware of the growing body of clinical evidence supporting the role of biologics and immunomodulators targeting immunoglobulin E (IgE)-mediated food allergies. This program will focus on clinical data for immunomodulators and emerging biologics that target IgE-mediated inflammatory pathways for the treatment of food allergies. It will also explore how emerging therapeutic approaches can be integrated into treatment protocols for food allergies by filling the existing gaps in patient management.

    Learning Objectives:

    • Analyze the treatment and socioeconomic burden associated with the contemporary approach in managing food allergies.
    • Show the trends in immunoglobulin E (IgE)-mediated food allergies through clinical trial data for immunomodulators and emerging biologics that target inflammatory pathways in food allergies.
    • Investigate strategies for the integration of treatment protocols aimed at alleviating the burden of IgE-mediated food allergies and filling the existing gaps in patient management, with a focus on exploring innovative therapeutic approaches.

      Program Manager:
      Kylie Ferrentino
      Pharmacy Times Continuing Education
      kferrentino@pharmacytimes.com

      Registration Link: Coming Soon

     Tuesday, Apr. 16, 2024|6-8pm

    Addressing the Gaps in Care in the Management of Generalized Pustular Psoriasis – Enhancing the Role of Managed Care

    Location: 206

    • Provider: Pharmacy Times Continuing Education
    • Supported by: Boehringer Ingelheim
    • Continuing education: Pharmacists, managed care
    • Contact hours: 1.5

      Program Description:

      Pustular psoriasis develops independently or in association with pre-existing psoriasis and may occur in a generalized or localized distribution.  Generalized pustular psoriasis (GPP) which is considered to be a phenotype of pustular psoriasis is defined as a rare, severe, recurrent, chronic life-threatening neutrophilic dermatological disease characterized by painful, sterile pus-filled blisters, which can abruptly appear over the body and cause infections, affect other organs and even result in death. Research has revealed that the IL-36 pathways play a pivotal role in the pathogenesis of GPP, and the introduction of anti-IL-36 therapies may change management of this disease. Managed care professionals need to be well-informed regarding the burdensome clinical manifestations, the comorbidities associated with GPP, and recent updates on emerging and FDA approved targeted therapies. In addition, it is imperative that managed care professionals continue to update their knowledge regarding the incidence, clinical presentation and health and economic burdens associated with GPP which will help elucidate the value of safety and efficacy data of recently approved and investigational agents to appreciate their role in care of patients with GPP. Equipped with this knowledge, managed care professionals can implement measures to improve patient access to appropriate therapies, therefore improving clinical outcomes and overall quality of life via lowering the burden of disease on individual patients and on healthcare resource utilization. The overall goals of this program are to expand the expertise and proficiency of managed care professionals on how to recognize the clinical presentation of GPP, their role in optimizing treatment regimens, and in contributing to the multidisciplinary care of GPP patients and ultimately enhancing care of patients suffering with this burdensome condition.

      Learning Objectives:

      Examine the clinical and economic burden associated with generalized pustular psoriasis. Analyze the evidence-based approach to care for the treatment of GPP and PPP and the clinical data for the available and emerging biologic therapies. Explore the managed care role in facilitating appropriate access to novel agents to improve clinical outcomes and healthcare resource utilization associated with the management of pustular psoriasis.

      Program Manager:
      Kylie Ferrentino
      Pharmacy Times Continuing Education
      kferrentino@pharmacytimes.com

      Registration Link: Coming Soon

       
    Keeping Pace With New Developments in Multiple Myeloma: Updates and Strategies to Optimize Bispecific Antibodies and CAR T-Cell Therapy

    Location: 224

    • Provider: Pharmacy Times Continuing Education
    • Supported by: Janssen Biotech, Inc, administered by Janssen Scientific Affairs, LLC
    • Continuing education: Pharmacists, managed care/oncology
    • Contact hours: 1.5

      Program Description:

      In individuals with relapsed/refractory multiple myeloma (MM) who required several prior treatments, bispecific antibodies (BsAbs) and other T-cell–directed therapies have demonstrated improved efficacy. Managed care professionals will be tasked with introducing these targeted agents and establishing treatment sequencing strategies within the existing framework of therapeutic options in MM. With improved understanding of the clinical impact of emerging BsAbs and chimeric antigen receptor (CAR) T-cell products, managed care professionals can develop clinical eligibility criteria and direct coverage issues for these therapies within the MM therapeutic landscape. Evidence will be presented regarding advantages and risks associated with these therapies at the clinical stage, as well as the need for strategies to continue to refine these treatments to make them more accessible. This program will examine available real-world data of the toxicity profiles of BsAbs and CAR T-cell therapies, duration of response, and other factors used to differentiate treatment selection between these immunotherapeutic agents to support optimal patient outcomes in relapsed/refractory MM.

      Learning Objectives:
       
    • Explore the patient- and disease-specific factors that drive treatment decisions for the use of novel immunotherapies in multiple myeloma (MM).
    • Examine the therapeutic landscape and the guideline-recommended use of bispecific antibodies (BsAbs) and chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory MM.
    • Analyze the recent safety and efficacy data from clinical trials of BsAbs and CAR T-cell therapies in the context of appropriate sequencing in the current MM care paradigms.
    • Explore best practices and operational strategies to optimize health care resource utilization, safety, and patient outcomes when using novel immunotherapies in the treatment of relapsed/refractory MM.

      Program Manager:
      Kylie Ferrentino
      Pharmacy Times Continuing Education
      kferrentino@pharmacytimes.com

      Registration Link: Coming Soon

    Wednesday, Apr. 17, 2024|11:30am-1:30pm 

    Adapting Managed Care Strategies in the Era of Precision Medicine for Hypertrophic Cardiomyopathy

    Location: 206

    • Provider: PVI, PeerView Institute for Medical Education
    • Supported by: Bristol Myers Squibb.
    • Continuing education: Managed care and specialty pharmacists, medical directors, cardiologists, advanced practice clinicians, and other healthcare professionals involved in the care of patients with HCM
    • Contact hours: 1.5

      Program Description:

      Hypertrophic cardiomyopathy (HCM) is a potentially fatal and frequently misdiagnosed disorder that affects approximately 1 in 200 people. If patients progress to severe symptomatic obstructive HCM (oHCM), interventional and pharmacological treatments are recommended to help reduce patient risks, manage symptoms, and improve quality of life. In contrast to conventional medical treatments that address only symptoms, a recently approved cardiac myosin inhibitor (CMI) targets the underlying pathophysiology. CMIs alleviate symptoms, improve functional outcomes, and are an established alternative to the more invasive septal reduction interventions. To realize the full potential of CMIs, this novel class must be integrated into treatment protocols for patients with oHCM—a challenge under many current pharmacy coverage policies. How should managed care and specialty pharmacists respond? 

      This PeerView Clinical Consults satellite symposium during the 2024 Academy of Managed Care Pharmacy (AMCP) Annual Meeting will answer that question and more. This activity integrates overviews of essential research with practical applications using actual patient scenarios. By the end of the symposium, learners will better grasp the HCM treatment journey, clinical recommendations, and evidence critical to uniting therapeutic decision-making with managed care strategies. Learners will then be able to take this knowledge and understand how to integrate it into updated managed care frameworks and team-based care. Register while seats are available to learn about this new era of precision medicine in HCM!

      Learning Objectives:
      ​​​​​​​
    • Identify the clinical and financial burdens experienced by patients with HCM that can contribute to suboptimal health and economic/resource utilization outcomes
    • Describe recommendations and evidence critical to aligning managed care strategies with therapeutic decision-making in oHCM
    • Integrate clinical features, pharmacoeconomic considerations, health equity, and patient-related factors into updated managed care frameworks and team-based care for oHCM

      Program Manager:

      Grayson Baldy
      PVI, PeerView Institute for Medical Education
      grayson.baldy@peerview.com

      Register Now
    Beyond Barriers: Managed Care Approaches to Ensure Equitable and Timely Access to BCMA-Directed Therapy in Multiple Myeloma

    Location: 215-216

    • Provider: Provided by ProCE, LLC in partnership with Clinical Care Options, LLC.
    • Supported by: Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
    • Continuing education: This program is intended for pharmacists who manage patients with multiple myeloma, including managed care pharmacists, as well as other managed care pharmacy professionals, pharmacy directors, chief pharmacy officers, and stakeholders in pharmacy practice.
    • Contact hours: 1.5

      Program Description:

      Managed care pharmacists have a pivotal role in incorporating BCMA-targeted therapies—both bispecific T-cell engagers and CAR T-cell therapies—into the evolving treatment milieu for patients with relapsed/refractory (R/R) multiple myeloma (MM), going beyond traditional drug procurement and distribution. The integrated care model positions managed care pharmacists at the center of patient care, bridging clinical advancements with cost management and patient accessibility.

      This program, presented by ProCE and CCO, proposes a 1.5-hour live satellite symposium at the 2024 Academy of Managed Care Pharmacy Annual Meeting. It aims to address current data on evaluating therapy-specific costs, formulary inclusion, patient access strategies, and the economic impact of adverse events associated with BCMA-targeted agents.

      The program incorporates case-based presentations, discussions on mitigating disparities, and strategies for optimizing sequencing in R/R MM, along with a question and answer session to encourage interactivity and engagement between the audience and the expert presenters to apply information to clinical practice.

      The proposed agenda includes:
      • Welcome, Opening Remarks
      • Navigating R/R MM: Unmet Needs, Individualized Treatment, and the Future of BCMA-Targeted Therapies
            o    Individualizing treatment selection, understanding current guideline recommendations, and the role of BCMA in shaping therapeutic strategies
      • Current and Emerging Evidence on BCMA-Directed Therapy in R/R MM and Managed Care Strategies for Quality and Equitable Care
            o    Delving into current use of CAR T-cell therapy and bispecific T-cell engagers in R/R MM, exploring their mechanisms of action, trial outcomes, and potential shifts in therapeutic dynamics
            o    Addressing critical aspects of CAR T-cell therapy and bispecific T-cell engager dosing, administration, REMS requirements, recognizing and managing adverse events, access barriers, patient adherence, interdepartmental synergy, and designing value-based pathways to balance clinical efficacy, patient outcomes, and cost-efficiency

    • Audience Question and Answer Session and Panel Discussion

    In summary, the program provides a comprehensive exploration of the evolving role of BCMA-targeted therapy in the MM treatment landscape, highlighting the crucial role of managed care pharmacists in ensuring equitable access, cost-effectiveness, and optimal outcomes for patients undergoing BCMA-directed therapy to facilitate practical application in clinical settings.

    Learning Objectives:

    •Assess the role of BCMA and BCMA-targeted therapies in R/R MM
    •Evaluate efficacy and safety evidence for BCMA-targeted therapies in patients with R/R MM and the impact of therapeutic choices in a managed care setting
    •Apply recommendations to identify and manage treatment-related AEs in patients treated with BCMA-targeted therapies for R/R MM
    •Integrate best practices in managed care with recent updates on BCMA-targeted therapies to optimize equitable access and informed formulary decisions for patients with R/R MM

    Faculty:

    Rebecca Gonzalez, PharmD, BCOP
    Blood and Marrow Transplant and Cellular Immunotherapy Clinical Pharmacist
    Moffitt Cancer Center
    Tampa, Florida

    Melissa Pozotrigo, PharmD, BCOP
    OncoHealth
    Atlanta, GA

    Program Manager:

    Suzanne Thatcher
    Clinical Care Options, LLC.
    sthatcher@clinicaloptions.com



    Register Now

    Wednesday, Apr. 17, 2024|6-8pm

    ManagedCareCGM.com Presents: Diabetes Quality Management–Trends and Opportunities for Continuous Glucose Monitoring in Managed Care Pharmacy

    Location: 215-216

    • Provider: Medical Education Resources
    • Supported by: Dexcom, Inc.
    • Continuing education: The primary target audience for this activity consists of managed care pharmacy directors, clinical pharmacists, quality directors, medical directors, members of the AMCP, and other managed health care professionals attending AMCP 2024.
    • 1.5 CPE/CME/CNE credit hours available

      Program Description:

      Backed by a growing body of clinical evidence and expert recommendations, the role of continuous glucose monitoring (CGM) in managed care has expanded rapidly in recent years. In addition to improving glycemic control and reducing hypoglycemic risk, CGM has demonstrated the potential to enhance patient engagement and self-management with associated reductions in resource utilization and medication use. As managed care professionals remain mindful of evolving quality measures and a wide array of treatment options, CGM represents a complimentary intervention for integration in comprehensive programming. This symposium will feature a PayerTalkCE format with the faculty discussing the latest trends and opportunities for CGM in high-quality, cost-effective diabetes disease management.

      Learning Objectives:

      Describe recent updates to HEDIS measures in diabetes care, including opportunities associated with glucose management indicator (GMI) and an increased focus on equity Describe the synergistic impact of CGM and GLP-1 agonists Outline health plan best practices and strategies for streamlined coverage, access, and value of CGM

      Program Manager:
      Allison Hartless
      Impact Education, LLC
      allison.hartless@impactedu.net

      Registration Link: Coming Soon

       
    Addressing the Gaps and Clinical Challenges in Chronic Lymphocytic Leukemia: Updates and Strategies for Managed Care

    Location: 224

    • Provider: Pharmacy Times Continuing Education
    • Supported by: Lilly and Beigene
    • Continuing education: Pharmacists, managed care/oncology
    • Contact hours: 1.5

      Program Description:

      Therapeutic developments in the treatment of chronic lymphocytic leukemia (CLL) have identified mechanisms for Bruton tyrosine kinase (BTK) inhibition that have shown to improve survival and quality of life outcomes for patients. Both covalent and noncovalent BTK inhibitors have been included in national treatment guidelines for patients with CLL, necessitating that pharmacists and managed care professionals understand the utility of these agents. This program will explore challenges in the treatment of patients with CLL, including development of resistance and treatment sequencing. Faculty experts will discuss updates to the growing body of evidence for the use of targeted therapy combinations and the emerging use of noncovalent BTK inhibitors within the treatment paradigm. Considerations for managed care professionals and pharmacists to assess adverse effects, disease progression, and the economic burden of indefinite treatment for patients with CLL will also be presented.

      Learning Objectives:

      • Break down the current evidence-based treatment approach for the use of small-molecule inhibitors in the management of chronic lymphocytic leukemia (CLL).
      • Analyze the real-world evidence and emerging trends to address the challenges in the treatment of patients with CLL.
      • Explore managed care strategies in mitigating the risk of major toxicities associated with small-molecule inhibitors in CLL.
      • Identify the managed care considerations on the evolving treatment paradigm for patients with CLL to optimize adherence and patient outcomes.

      Program Manager:
      Kylie Ferrentino
      Pharmacy Times Continuing Education
      kferrentino@pharmacytimes.com

      Registration Link: Coming Soon

    Thursday, Apr. 18, 2024|7-9am
     

    Advancing Patient Outcomes in Hidradenitis Suppurativa: Updates and Strategies for Managed Care

    Location: 215-216

    • Provider: Pharmacy Times Continuing Education
    • Supported by: Novartis
    • Continuing education: Pharmacists, managed care
    • Contact hours: 1.5

      Program Description:

      A chronic, inflammatory disease of the hair follicles, hidradenitis suppurativa (HS) presents with painful nodules and lesions typically near sweat glands. Since HS is not curable, treatment plans include lifestyle changes, topical agents, and antibiotics for infection, wound care, and pain management. Emerging therapies have been introduced that target cytokines such as IL-17 and Janus kinase pathways. People living with HS may experience years of undertreatment or incorrect treatment, as well as complications that may impact physical, psychological, socioeconomic, and quality-of-life factors. Complexities from both the disease and underlying comorbidities also lead to higher health care utilization costs. Managed care pharmacists need to be aware of the challenges associated with HS so they can allocate health care resources accordingly, reduce treatment disparities, help patients gain appropriate access to new therapies, and alleviate the cost-associated burden. This activity includes an overview of the clinical presentation of HS, severity scoring systems, emerging treatment options, and information on costs and health care utilization rates.

      Learning Objectives:
       

      • ​​​​​​​Identify the challenges in treatment, the burden of disease, and the severity scoring systems that guide the treatment approach for hidradenitis suppurativa
      • ​​​​​​​Examine recent clinical safety and efficacy data for current and investigational agents for moderate to severe HS
      • ​​​​​​​​​​​​​​Investigate managed care strategies to facilitate appropriate access to new treatments for patients with HS

        Program Manager:
        Kylie Ferrentino
        Pharmacy Times Continuing Education
        kferrentino@pharmacytimes.com

        ​​​​​​​Registration Link: Coming Soon